Longeveron shares have lost nearly two-thirds of their value in two sessions after laromestrocel failed the primary endpoint in the ELPIS II study for hypoplastic left heart syndrome, forcing the biotechnology company to reassess its development strategy, conserve cash and review options to maximize shareholder value.
European regulators have backed once-weekly Sogroya for children with idiopathic short stature, potentially giving Novo Nordisk the first EU-approved growth hormone specifically for the condition while expanding a rare-endocrine franchise beyond growth hormone deficiency.
IntraBio’s AQNEURSA has become the first approved treatment for ataxia in people with ataxia-telangiectasia after a randomized Phase 3 trial showed a significant improvement in neurological function. The approval ends decades without a specific therapy for the disorder’s ataxia, but it does not resolve whether levacetylleucine can slow long-term neurodegeneration or alter the immune, pulmonary
Xenon Pharmaceuticals shares suffered their biggest recent sell-off after the company paused new enrollment in late-stage depression studies over neuropsychiatric adverse events, overshadowing an important FDA filing for azetukalner in focal seizures.
Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen over seven patents tied to its proposed Opdivo biosimilar ABP 206, opening an important legal battle around a cancer drug that generated more than $10 billion in 2025.
Gilead Sciences has expanded royalty-free licensing agreements with six generic manufacturers to cover investigational once-yearly lenacapavir for HIV prevention while the Phase 3 PURPOSE 365 study is still underway. The decision deliberately moves manufacturing and access planning ahead of regulatory certainty, potentially shortening the years-long delay that has historically separated pharmaceutical innovation from broad availability
Ultragenyx Pharmaceutical has secured full FDA approval for Fayuvi, the first treatment for Sanfilippo syndrome Type A, giving the rare-disease biotech a major commercial catalyst only weeks after a Phase 3 setback erased nearly half its market value.
Merck & Co.’s Keytruda plus Padcev has won a positive European regulatory opinion for perioperative treatment of resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, potentially expanding an already important oncology franchise into a broader earlier-stage population.
Johnson & Johnson’s final PAPILLON analysis found median overall survival of 34.3 months with first-line RYBREVANT plus chemotherapy versus 27.9 months with chemotherapy, but the protocol-specified comparison was not statistically significant. With 76% of eligible chemotherapy patients later receiving amivantamab, the trial has become a case study in how effective crossover can obscure overall-survival differences.
Aptitude Medical Systems has secured traditional FDA 510(k) clearance for its next-generation Metrix COVID Test as pandemic-era emergency authorizations approach their scheduled end. The deeper opportunity is not COVID testing itself, but whether a compact RT-LAMP platform can make laboratory-quality molecular diagnostics economically practical across urgent care, physician offices and other decentralized settings.